News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
145–180
Matches
411
Sources here
19
Companies here
12
Search results Stored financial headlines

Active search

411 matching headlines

Ticker or company: QUEMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Segall Bryant & Hamill LLC Sells 94,659 Shares of Frequency Electronics, Inc. $FEIM

Segall Bryant & Hamill LLC significantly reduced its stake in Frequency Electronics, Inc. (FEIM) by selling 94,659 shares, a 30.9% decrease, during the first quarter. Despite this, institutional investors still collectively own 58.6% of the company. Frequency Electronics recently missed analyst estimates for both …

FEIM main company
Sharemaestro market context Trend signal active 52 weeks +171.4% FEIM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

HireQuest Number of Employees 2026 | Employee Count & Headcount Data

HireQuest, Inc. (HQI) had approximately 76,051 total employees worldwide as of March 2026, representing a 0.1% growth from 2023. The company is actively hiring with 358 active job postings in 2026, despite a significant decline in job postings from 2025. The workforce is primarily …

HQI main company
Sharemaestro market context Trend signal active 52 weeks +75.6% HQI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

DGX|Quest Diagnostics Inc|Price:233.010|Chg%:-1.190

This article provides an overview of Quest Diagnostics Inc. (DGX), detailing its current stock performance, key financial figures, and analyst ratings. The company is highlighted for its healthy fundamentals, high growth potential, and strong institutional ownership, with analysts generally rating it as a "Buy" …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Quest Diagnostics Incorporated (DGX) jumps 8.2% as volume nearly doubles

The diagnostics stock’s weekly advance gained confirmation from heavier turnover and positive momentum readings.

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Frequency Electronics Inc (FEIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Frequency Electronics Inc (FEIM), highlighting its price momentum score of 5.63 within its industry and noting its current trading range between support at $45.90 and resistance at $77.20. It details various technical indicators, categorizing them as sell, …

FEIM main company
Sharemaestro market context Trend signal active 52 weeks +171.4% FEIM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?

Quest Diagnostics Incorporated DGX has rallied as earnings momentum improved, estimates moved higher and demand broadened across its testing platform. The buy case is not one-sided. The stock's advance has lifted valuation closer to its five-year high, while leverage, cost pressure and reimbursement uncertainty …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AQST|Aquestive Therapeutics Inc|Price:3.725|Chg%:+0.125

This article provides a comprehensive stock analysis of Aquestive Therapeutics Inc (AQST) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company has healthy fundamentals, high growth potential, and its valuation is considered fairly …

AQST main company
Sharemaestro market context Price above Trend Line 52 weeks +6.8% AQST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Frequency Electronics (NASDAQ: FEIM) Edenbrook funds sell 652,174 shares

Entities linked to Edenbrook Capital, including Edenbrook Value Fund, LP and Edenbrook Long Only Value Fund, LP, reported selling a total of 652,174 shares of Frequency Electronics (NASDAQ: FEIM) common stock on July 28, 2026, at a price of $57.50 per share. The transactions, …

FEIM main company
Sharemaestro market context Trend signal active 52 weeks +171.4% FEIM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Frequency Electronics, Inc. (FEIM) holder Edenbrook details share sale and 11% stake

Edenbrook Capital, LLC and its affiliated funds maintain an 11.33% beneficial ownership in Frequency Electronics, Inc. (FEIM) following a recent sale of 652,174 common shares at $57.50 per share through an underwritten offering by Morgan Stanley & Co. LLC. Despite the sale, Edenbrook remains …

FEIM main company
Sharemaestro market context Trend signal active 52 weeks +171.4% FEIM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Frequency Electronics (NASDAQ: FEIM) raises $62.5M in $57.50 share sale

Frequency Electronics, Inc. (NASDAQ: FEIM) successfully raised approximately $62.5 million in gross proceeds through an underwritten offering, selling 1,086,957 new shares at $57.50 per share. Concurrently, selling stockholders also divested 652,174 shares, bringing the total offering to 1,739,131 shares. The underwriters have a 30-day …

FEIM main company
Sharemaestro market context Trend signal active 52 weeks +171.4% FEIM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Quest Diagnostics’ 8.6M-share advance tightens the chase toward its 52-week high

DGX gained 8.2% in the latest week on twice its 13-week volume average, leaving the clinical-lab stock 4.2% below its 52-week high while valuation and reversal risk argue for confirmation.

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Discipline and Rules-Based Execution in HQI Response

This article provides an AI-driven analysis for Hirequest, Inc. (NYSE: HQI), highlighting a strong "Overweight Bias" based on sentiment across all horizons. It identifies a mid-channel oscillation pattern and an exceptional 40.5:1 risk-reward setup targeting a 12.7% gain. The report includes three distinct trading …

HQI main company
Sharemaestro market context Trend signal active 52 weeks +75.6% HQI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Argus Research Adjusts Quest Diagnostics Price Target to $260 From $225, Maintains Buy Rating

Argus Research has increased its price target for Quest Diagnostics (DGX) to $260 from $225, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's future performance. The article also notes other recent analyst adjustments for Quest …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026

Quest Diagnostics (DGX) is propelled by broad testing demand, expanded payer access, advanced diagnostics, and strategic partnerships, supporting revenue growth in 2026. The company's base business benefits from physician, hospital, and consumer channels, while advanced diagnostics in multiple health areas and acquisitions contribute significantly. …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Labcorp raises annual profit forecast on strong testing demand

By Sahil Pandey July 30 (Reuters) - Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, ‌as steady demand for diagnostic testing and growth in ‌its drug-development services business boosted performance. Shares of the company fell about 6% …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Bacterial vaginosis patients were over 3x more likely to have an STI

A national study by Quest Diagnostics and Hologic, analyzing data from over 1.5 million U.S. women, found that 12% of women positive for bacterial vaginosis (BV) also had at least one non-viral sexually transmitted infection (STI), compared to 3.8% of BV-negative women. BV positivity …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

QUEST DIAGNOSTICS INC : JP MORGAN RAISES TARGET PRICE TO $250 FROM $220

JP Morgan has increased its target price for Quest Diagnostics Inc. from $220 to $250. This change in target price suggests an updated positive outlook for the company's stock by the financial institution. The specific reasons for this revised target are not detailed in …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

HQI|Hirequest Inc|Price:13.680|Chg%:-0.135

This article provides a comprehensive stock analysis of Hirequest Inc (HQI) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Professional & Commercial Services industry. Key insights include high institutional ownership, a Strong Buy rating from analysts with an …

HQI main company
Sharemaestro market context Trend signal active 52 weeks +75.6% HQI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $248.86, Implies 6% Upside

The average 12-month price target for Quest Diagnostics Incorporated (DGX) stock has been raised by analysts from $246.6 to $248.86, indicating an approximate 6% potential upside from its July 29th closing price. The consensus rating from 20 analysts remains a "Buy," with 9 Buys, …

DGX main company QUEST main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Quest Diagnostics SVP Mark Delaney sells $376k in shares

Mark E. Delaney, SVP and CCO at Quest Diagnostics Inc. (NASDAQ: DGX), sold 1,600 shares for $376,288 on July 28, 2026, conducted under a Rule 10b5-1 sales plan. This transaction occurred as the stock neared its 52-week high, after a significant 12% gain. The …

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Price to sales forward of Quetta Acquisition Corporation – NASDAQ:QETA

This article provides financial data for Quetta Acquisition Corporation (NASDAQ: QETA), specifically focusing on its Price to Sales forward metric. The content indicates that for the specified period, the value is not available, showing "No trades." The article is hosted on TradingView, a financial …

QETA main company
Sharemaestro market context Trend signal active 52 weeks +6.6% · Next-week setup negative 34.2% QETA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Quest Diagnostics Incorporated (DGX) draws heavier weekly trading as trend stays active

The healthcare diagnostics stock extended its weekly advance, with volume and momentum readings adding confirmation rather than contradiction.

DGX main company
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1% DGX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics (NASDAQ: AQST) will release its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will then host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these …

AQST main company
Sharemaestro market context Price above Trend Line 52 weeks +6.8% AQST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aquestive Therapeutics Inc (AQST), highlighting its current price momentum score, support and resistance levels, and indicator readings. It details various technical indicators like MACD, RSI, and moving averages, offering "Sell", "Neutral", and "Buy" signals. The analysis suggests …

AQST main company
Sharemaestro market context Price above Trend Line 52 weeks +6.8% AQST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

QRHC|Quest Resource Holding Corp|Price:1.320|Chg%:+0.070

TradingKey provides a comprehensive analysis of Quest Resource Holding Corp (QRHC), highlighting its stable fundamentals, significant growth potential, and fair valuation within the Professional & Commercial Services industry. Analysts have rated QRHC as a Buy, with a target price indicating substantial upside. Despite strong …

QRHC main company
Sharemaestro market context Price above Trend Line 52 weeks -4.8% QRHC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Quest Resource Holding Corp (QRHC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Quest Resource Holding Corp (QRHC), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 31, 2026, QRHC has a price momentum score of 4.25 and is trading …

QRHC main company
Sharemaestro market context Price above Trend Line 52 weeks -4.8% QRHC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context